4501 X St.
Sacramento, CA 95817
Maywood , Illinois
University of Illinois at Chicago
Hematology and Oncology
American Board of Internal Medicine, Medical Oncology, 2002
American Board of Internal Medicine, Medical Oncology, 1994
American Board of Internal Medicine, 1990
Honors and Awards:
U.S. Patent 62,180,089: "Avemar and Purified Low Molecular Weight Avemar Proteins for the Treatment of Non-Hodgkin's Lymphoma: Joseph Tuscano, MD and Robert O'Donnell, MD, PhD, 2010
U.S. Patent 6,217,871 "Antigenic Epitopes with Lym-1 Reactivity and Uses Thereof": Larry Rose, PhD, Claude Meares, PhD and Robert o"Donnell MD, PhD, 2001
Bank of America Giannini Foundation Medical Research Fellowship, 1992-93
American Cancer Society Clinical Fellowship, 1990
Acting Chief Resident, UC Davis Medical Center (1 month), 1988, 1989
University of Illinois Research and Teaching Assistantships, 1984-87
University of Illinois Graduate College Fellowship, 1983
Illinois State Scholarship, 1973-77
Loyola University of Chicago Merit Scholarship, 1973-77
Select Recent Publications:
Tuscano JM, YP Ma, SM Martin, J Kato, RT O'Donnell. The Bs20x22 Anti-CD20-CD22 Bispecific Antibody has more Lymphomacidal Activity than do the Parent Monoclonal Antibodies Alone.. Cancer Immunol. Immunother., 60: 771-780.
Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res, 16(10): 2760-8.
2009 O'Donnell RT, YP Ma, HC McKnight, D Pearson, JM Tuscano. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol lmmunother. 58(12):2051-2058.
2009 O'Donnell RT, SM Martin, YP Ma, WC Zamboni, JM Tuscano. Development and characterization of CD22-targeted pegylated liposomal doxorubicin (IL-PLD). Invest New Drugs. In press.
2009 O'Donnell RT, D Pearson, HC McKnight, YP Ma, JM Tuscano. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother. Mar 18. [Epub ahead of print]
2009 O'Donnell RT, D Pearson, HC McKnight, YP Ma, JM Tuscano. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-Hodgkin's lymphoma cells. Leuk Res. Feb 21. [Epub ahead of print]
2009 Martin SM, RT O'Donnell, DL Kukis, C Abbey, H McKnight, JL Sutcliffe, JM Tuscano. Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin lymphoma xenografts. Mol Imaging BioI. 11(2):79-87.
2008 Pearson DP, RT O'Donnell, K Lam, JM Tuscano. CD22-binding peptides derived from anti-CD22 ligand blocking antibodies retain the targeting and cell killing properties of the parent antibodies and may serve as a drug delivery vehicle. International Journal of Peptide Research and Therapeutics, 14:237-246.
2007 Schillaci O, GL DeNardo, SJ DeNardo, DS Goldstein, LA Kroger, RT O'Donnell, KR Lamborn. Effect of anti-lymphoma antibody, 131 I-Lym-1 on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm, 22(4):521-30.
2007 Semrad TJ, RT O'Donnell, T Wun, H Chew, D Harvey, H Zhou, RH White. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106(4):601-608.